EXAS

Exact Sciences Corporation (NASDAQ:EXAS) is a leading molecular diagnostics company founded in 1995 and headquartered in Madison, Wisconsin. The company went public in 2001 and has evolved from a startup focused on colorectal cancer screening into a comprehensive cancer diagnostics platform. Exact Sciences is best known for developing <b>Cologuard</b>, a non-invasive stool-based DNA test that revolutionized colorectal cancer screening by offering patients an alternative to traditional colonoscopy. The company has expanded its portfolio through strategic acquisitions and internal development to include precision oncology testing services, positioning itself as a major player in the cancer diagnostics industry with over 4.6 million test results delivered annually.